Goldman Sachs Downgrades Intellia Therapeutics to Neutral, Announces $32 Price Target
Portfolio Pulse from Benzinga Newsdesk
Goldman Sachs analyst Salveen Richter downgraded Intellia Therapeutics (NTLA) from Buy to Neutral and set a price target of $32.

February 23, 2024 | 6:34 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Goldman Sachs downgraded Intellia Therapeutics to Neutral from Buy and set a $32 price target.
Analyst downgrades typically lead to a negative short-term reaction in the stock price as they often reflect a less optimistic outlook on the company's future performance. The downgrade from a prestigious firm like Goldman Sachs, coupled with a specific price target, can influence investor sentiment and potentially lead to a decrease in stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100